null

null

null

null

null

null

null

null

null

null

null

null

null

-0.13x Total Debt / Equity (Negative equity)

Minimal direct debt sensitivity; pre-revenue stage company with equity-funded operations, so 20bp rate move has negligible P&L impact but raises cost of future capital raises

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-source hemostatic gauze raw material suppliers and FDA-registered contract manufacturers; no significant geopolitical chokepoints identified given domestic US focus

Effectively zero international revenue; company operates exclusively in US pre-commercialization stage, so sovereign currency devaluation exposure is null

100% US-based operations and target market; no material foreign currency revenue exposure across any international market

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Contract manufacturer for HemoStyp gauze likely represents critical single-source dependency; substitution would require re-validation and FDA notification, creating high switching friction

Not cloud-dependent; medical device/wound care product company with physical manufacturing; cloud termination would affect administrative functions only, not core operations

Biomedical/medical device manufacturer seeking hospital and military procurement contracts; secondary model involves licensing or co-development partnership revenues

Minimal API coupling risk; company is a physical medical device firm with no significant software platform or API-dependent revenue architecture

Low Howey risk; revenue model is product sales of FDA-regulated wound care devices, not investment contracts; no token or profit-sharing scheme identified

Very High

Low GDPR/CCPA exposure; no consumer data platform or SaaS product; minimal PII collected beyond standard B2B procurement contacts

Negligible antitrust risk; company holds de minimis market share in hemostatic wound care; market dominated by large incumbents like 3M and Z-Medica

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently pre-revenue to near-zero revenue; target model is transactional B2B purchase orders from hospitals and government agencies, not recurring subscription

Direct product sales of HemoStyp hemostatic gauze to hospitals, military, EMS, and first responders via GPO contracts and government procurement channels

Cost-plus pricing constrained by GPO contract structures and government procurement pricing; limited pricing power versus established hemostatic competitors with clinical evidence

Low to moderate; commodity-adjacent wound care market with price-sensitive government buyers; differentiation via bovine collagen mechanism provides modest premium justification

Estimated 40–60% gross margin target for medical device consumables at scale; current margins undefined due to pre-commercial stage and low volume production costs

No free-rider problem; physical product with per-unit purchase requirement; hospital formulary inclusion is key gating risk rather than churn in traditional SaaS sense

Revenue growth is largely headcount-sublinear; manufacturing scales via contract manufacturer capacity, not internal headcount; sales force expansion needed for hospital network penetration

Marginal cost of growth primarily in sales rep additions and regulatory affairs; manufacturing COGS declines with volume; no significant software or infrastructure scaling cost

Not applicable; company does not operate a franchise network

At 10x scale, CAC economics improve via GPO contract leverage; however, hospital formulary approval process remains fixed cost regardless of scale, compressing early-stage unit economics

No meaningful network effects; medical device consumable product with no platform dynamic; clinical adoption is linear and institution-by-institution

Low AI displacement risk; core product is a physical hemostatic gauze; AI cannot replicate wound care consumable manufacturing or substitute clinical application

High recession resistance; trauma wound care and hemostasis are non-discretionary medical necessities; military and emergency medical budgets are relatively recession-insulated

US military and Department of Defense procurement accounts represent highest-priority target segment with large addressable contract volumes

Acute care hospitals, trauma centers, and EMS agencies via group purchasing organization contracts represent secondary commercial segment

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocation is R&D and regulatory pathway focused; no legacy infrastructure to reallocate from; capex directed toward FDA clearance expansion and clinical study funding

0001096938

UEEC